Baidu
map

延长他汀类药物使用 降低肺癌死亡风险

2015-05-05 佚名 生物谷

近日一项研究表明,肺癌病人在诊断前或诊断后服用他汀类药物可降低肺癌造成的死亡风险。 一名来自北爱尔兰的研究人员指出:这项研究为肺癌病人服用他汀类药物可降低肺癌造成的死亡风险提供了一些证据。但他同时也说道,两者之间但关系并不是特别显著,他汀类药物服用者可能在其他一些方面与未服用他汀类药物的病人存在不同,导致他们因肺癌造成的死亡率降低,但这一发现仍值得进一步的观察研究。 在该项研究

近日一项研究表明,肺癌病人在诊断前或诊断后服用他汀类药物可降低肺癌造成的死亡风险。
 
一名来自北爱尔兰的研究人员指出:这项研究为肺癌病人服用他汀类药物可降低肺癌造成的死亡风险提供了一些证据。但他同时也说道,两者之间但关系并不是特别显著,他汀类药物服用者可能在其他一些方面与未服用他汀类药物的病人存在不同,导致他们因肺癌造成的死亡率降低,但这一发现仍值得进一步的观察研究。
 
在该项研究中,研究人员利用了接近1,4000份在1998年到2009年间诊断为肺癌的病人资料,并将这些病人的处方纪录与截至2012年的病人死亡数据进行了分析。结果发现在诊断后存活超过6个月的病人中,服用他汀类药物的病人因肺癌导致的死亡率有11%的下降,但这一数据不存在统计学意义。而服用了超过12个月他汀类药物的肺癌病人,因肺癌导致的死亡率下降了19%,并且这一结果存在统计学意义。该研究所有病人中,在诊断前就服用他汀类药物的病人其因肺癌导致的死亡率显著下降了12%。
 
最后,研究人员指出,这一结果在非小细胞肺癌病人和小细胞肺癌病人之间并没有什么不同,并且他们希望通过扩大肺癌病人数据量来进一步验证这一发现。

原始出处:

Chris R. Cardwell1,*, Úna Mc Menamin1, Carmel M. Hughes2, and Liam J. Murray1,3.Statin Use and Survival from Lung Cancer: A Population-Based Cohort Study.Cancer Epidemiol Biomarkers Prev May 2015.doi: 10.1158/1055-9965.EPI-15-0052

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044365, encodeId=1af020443653a, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Feb 14 12:03:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971526, encodeId=c40119e1526f9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Mar 03 03:03:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255512, encodeId=88aa1255512cc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 07 04:03:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22657, encodeId=aef72265e1b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue May 05 22:40:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044365, encodeId=1af020443653a, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Feb 14 12:03:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971526, encodeId=c40119e1526f9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Mar 03 03:03:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255512, encodeId=88aa1255512cc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 07 04:03:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22657, encodeId=aef72265e1b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue May 05 22:40:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044365, encodeId=1af020443653a, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Feb 14 12:03:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971526, encodeId=c40119e1526f9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Mar 03 03:03:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255512, encodeId=88aa1255512cc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 07 04:03:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22657, encodeId=aef72265e1b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue May 05 22:40:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044365, encodeId=1af020443653a, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Feb 14 12:03:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971526, encodeId=c40119e1526f9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Mar 03 03:03:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255512, encodeId=88aa1255512cc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 07 04:03:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22657, encodeId=aef72265e1b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue May 05 22:40:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
    2015-05-05 huaxipanxing

    看看

    0

相关资讯

郭艺芳:颈动脉斑块需用他汀治疗吗?

近年来颈动脉超声检查普遍开展,很多患者或健康查体者被发现有颈动脉斑块。存在颈动脉斑块者需要应用他汀治疗吗?这是临床上经常被患者问到的问题。这个问题无法一概而论,应结合患者的颈动脉狭窄程度、是否存在心血管病或心血管病危险因素以及低密度脂蛋白胆固醇(LDL-C)水平综合考虑。 若颈动脉斑块导致了颈动脉明显狭窄(狭窄≥50%),其处理原则与确诊冠心病或缺血性卒中相同(均属于动脉粥样硬化

JACC:冠心病事件患者出院后未进行充分高强度他汀治疗

AHA/ACC指南中建议,冠心病患者应进行高强度他汀治疗降血脂,从而减少动脉粥样硬化性心血管疾病的风险,尤其是急性冠脉综合症的患者出院后的患者。然而,只有少部分研究有报道冠心病事件发生后患者应用高强度他汀治疗。出院后高强度他汀治疗的研究并不够充分。因此,纽约西奈山医学院Rosenson RS等人研究了冠心病事件发生后使用高强度他汀治疗患者的比例,分析了入院前后他汀治疗强度的相关性,其研究成果发

Lancet:他汀类药物在心血管事件一级预防中的作用无性别差异

研究背景: 他汀类药物治疗在女性中的心血管事件一级预防作用是否与男性一致,一直备受争议。研究人员在胆固醇治疗研究者协作组(Cholesterol Treatment Trialists' (CTT) Collaboration)数据库,对他汀类药物的临床试验进行了荟萃分析,即在于比较他汀类药物在男性和女性人群中的疗效。 研究方法: 研究人员供收集27项他汀类药物临床试验数据,其中

Baidu
map
Baidu
map
Baidu
map